Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Gastroesophageal Reflux Disease Market in the US to Show Promising Growth at a CAGR of 6% During the Forecast Period (2025-2034) | DelveInsight

      DelveInsight Logo

      News provided by

      DelveInsight Business Research, LLP

      Jan 22, 2026, 17:31 ET

      Share this article

      Share this article


      The gastroesophageal reflux disease market continues to be constrained by a limited number of approved treatment options and persistent unmet needs, particularly among patients who do not achieve adequate control with PPIs. Nevertheless, advancements in diagnostic approaches and the introduction of next-generation therapies, such as BLI5100 (Braintree Laboratories), linaprazan glurate (Cinclus Pharma), and others, are expected to sustain market growth from 2025 to 2034.

      LAS VEGAS, Jan. 22, 2026 /PRNewswire/ -- DelveInsight's Gastroesophageal Reflux Disease Market Insights report includes a comprehensive understanding of current treatment practices, gastroesophageal reflux disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

      Gastroesophageal Reflux Disease Market Summary

      • The market size for gastroesophageal reflux disease was found to be USD 3.3 billion in the United States in 2024.
      • VOQUEZNA established its early presence as the first US P-CAB, and is projected to expand rapidly over the next decade as demand rises for faster and more durable acid suppression beyond conventional PPIs.
      • The United States recorded approximately 33 million diagnosed prevalent GERD cases in 2024, highlighting the substantial and growing clinical burden of reflux disease across the population.
      • Leading gastroesophageal reflux disease companies, such as Braintree Laboratories, Cinclus Pharma, and others, are developing new GERD treatment drugs that can be available in the GERD market in the coming years. 
      • The promising gastroesophageal reflux disease therapies in clinical trials include BLI5100 (Tegoprazan), Linaprazan glurate, and others.

      Discover GERD market size by revenue and patient population @ https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

      Key Factors Driving the Growth of the Gastroesophageal Reflux Disease Market 

      • Rising GERD Prevalence: According to DelveInsight, the United States recorded approximately 33 million diagnosed prevalent GERD cases in 2024, highlighting the substantial and growing clinical burden of reflux disease across the population.
      • Dominance of VOQUEZNA: VOQUEZNA (vonoprazan), developed by Phathom Pharmaceuticals, is the first approved PCAB for GERD in the US and delivers faster onset, more consistent acid suppression, and superior early healing versus lansoprazole, positioning it as a strong option for patients with high acid burden, nocturnal symptoms, or relapse during PPI tapering.
      • Launch of Emerging Therapies: During the forecast period (2025–2034), pipeline candidates such as BLI5100 (tegoprazan) (Braintree Laboratories), Linaprazan glurate (Cinclus Pharma), and others are expected to drive growth in the 7MM GERD market.
      • Emerging Role of Tegoprazan in Acid Suppression Therapy: The introduction of Tegoprazan, a potassium-competitive acid blocker, in Phase III trials presents an opportunity to address unmet needs and expand treatment options.

      Gastroesophageal Reflux Disease Market Analysis

      • GERD management is still dominated by generic PPIs and H2RAs, driven by long-standing physician familiarity and widespread OTC availability.
      • Despite their use, PPIs show several drawbacks, including delayed onset of action, variable and incomplete acid suppression, reduced nocturnal control, and limited healing efficacy in moderate-to-severe erosive esophagitis (LA Grade C/D).
      • Developed by Phathom Pharmaceuticals, VOQUEZNA is the first PCAB-approved for GERD in the U.S., offering faster onset, more consistent acid suppression, and superior early healing compared with lansoprazole.
      • VOQUEZNA is well-suited for patients with high acid burden, persistent nocturnal symptoms, or relapse during PPI tapering.
      • Two next-generation PCABs, BLI5100 (tegoprazan) from Braintree Laboratories (Sebela Pharmaceuticals) and linaprazan glurate from Cinclus Pharma, are in late-stage development and are expected to expand treatment options and compete with VOQUEZNA for patients inadequately controlled on standard PPI therapy.

      Gastroesophageal Reflux Disease Competitive Landscape

      BLI5100 (tegoprazan) from Braintree Laboratories (Sebela Pharmaceuticals) and linaprazan glurate from Cinclus Pharma are in late-stage development and are expected to compete with VOQUEZNA by providing additional options for patients who remain inadequately controlled on standard PPI therapy.

      Braintree Laboratories' BLI5100 (tegoprazan) is a next-generation potassium-competitive acid blocker (P-CAB) to treat acid-related gastrointestinal disorders. Administered orally, it achieves rapid and durable suppression of gastric acid by directly blocking the proton pump within parietal cells, through a mechanism independent of H⁺/K⁺-ATPase activation that characterizes proton pump inhibitors (PPIs). Its molecular architecture allows interaction nearer the luminal surface of the pump, supporting a faster onset of action compared with conventional PPIs and potentially other P-CABs. BLI5100 is currently under evaluation in two Phase III clinical studies in the United States for erosive esophagitis and non-erosive reflux disease (NERD).

      Cinclus Pharma's Linaprazan glurate is also a next-generation P-CAB and serves as the prodrug of linaprazan, originally discovered by AstraZeneca. It features a differentiated mechanism of action, enhanced pharmacokinetic properties, and the potential for improved therapeutic effectiveness. Clinical data indicate greater gastric acid suppression than that achieved with existing treatment options. The agent is being advanced for patients with moderate-to-severe erosive GERD and Helicobacter pylori infection who have an inadequate response to currently available therapies.

      The anticipated launch of these emerging therapies are poised to transform the gastroesophageal reflux disease market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the gastroesophageal reflux disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      Discover more about the latest drugs and therapies for GERD @ Gastroesophageal Reflux Disease Drugs Market 

      Recent Developments in the Gastroesophageal Reflux Disease Market

      • In October 2025, Cinclus Pharma Holding reported that it received favorable guidance from the US FDA following a recent Chemistry, Manufacturing, and Controls (CMC) meeting, endorsing the continued development of its lead candidate, linaprazan glurate.
      • In October 2025, Phathom Pharmaceuticals announced that the results of additional analyses from its pivotal Phase III pHalcon-NERD-301 trial evaluating VOQUEZNA (vonoprazan) tablets in patients with NERD have been published in the American Journal of Gastroenterology.
      • In August 2025, Braintree Laboratories, a subsidiary of Sebela Pharmaceuticals, reported positive topline results from the 24-week maintenance phase of the pivotal Phase III TRIUMpH study evaluating tegoprazan, a novel P-CAB, for the treatment of GERD.

      What is Gastroesophageal Reflux Disease?

      Gastroesophageal reflux disease (GERD) is a chronic digestive disorder in which stomach acid and, at times, bile flow back into the esophagus, the tube that connects the mouth to the stomach. This backflow, known as acid reflux, occurs when the lower esophageal sphincter (LES), a ring of muscle at the junction of the esophagus and stomach, becomes weak or relaxes inappropriately. Repeated exposure of the esophagus to stomach acid can irritate and damage its lining, leading to symptoms such as persistent heartburn, acid regurgitation, chest discomfort, difficulty swallowing, and chronic cough. If left untreated, GERD can result in complications including esophagitis, strictures, Barrett's esophagus, and an increased risk of esophageal cancer.

      Gastroesophageal Reflux Disease Epidemiology Segmentation

      The gastroesophageal reflux disease epidemiology section provides insights into the historical and current gastroesophageal reflux disease patient pool and forecasted trends for the leading markets. In 2024, NERD accounted for the majority of GERD cases in the United States, with approximately 23 million cases, while erosive esophagitis represented a smaller share at around 10 million cases.

      The gastroesophageal reflux disease treatment market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

      • Prevalent Cases of GERD 
      • Diagnosed Prevalent Cases of GERD
      • Gender-specific Cases of GERD 
      • Age-specific Cases of GERD 
      • Type-specific Cases of GERD
      • Grade-specific Cases of GERD
      • Total Treated Cases of GERD

      Gastroesophageal Reflux Disease Market Forecast Report Metrics

      Details

      Study Period

      2020–2034

      Coverage

      7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

      Gastroesophageal Reflux Disease Market CAGR (US)

      6 %

      Gastroesophageal Reflux Disease Market Size in 2024 (US)

      USD 3.3 Billion

      Key Gastroesophageal Reflux Disease Companies

      Braintree Laboratories, Cinclus Pharma, Phathom Pharmaceuticals, Takeda, and others

      Key Gastroesophageal Reflux Disease Therapies

      BLI5100 (Tegoprazan), Linaprazan glurate, VOQUEZNA, and others

      Scope of the Gastroesophageal Reflux Disease Market Report

      • Therapeutic Assessment: Gastroesophageal Reflux Disease current marketed and emerging therapies
      • Gastroesophageal Reflux Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Gastroesophageal Reflux Disease Drugs and Market Outlook
      • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
      • Unmet Needs, KOL's views, Analyst's views, Gastroesophageal Reflux Disease Market Access and Reimbursement

      Download the report to understand what will drive the GERD market in the next decade @ Gastroesophageal Reflux Disease Market Forecast

      Table of Contents

      1

      Gastroesophageal Reflux Disease Market Key Insights

      2

      Gastroesophageal Reflux Disease Market Report Introduction

      3

      GERD Market Overview at a Glance

      3.1

      Market Share (%) Distribution of GERD by Therapies in 2024 in the 7MM

      3.2

      Market Share (%) Distribution of GERD by Therapies in 2034 in the 7MM

      4

      Epidemiology and Market Methodology

      5

      Executive Summary

      6

      Key Events

      7

      Disease Background and Overview

      7.1

      Introduction

      7.2

      Signs and Symptoms

      7.3

      Causes

      7.4

      Risk Factors

      7.5

      Prognosis

      7.6

      Pathophysiology

      7.7

      Complications

      7.8

      Diagnosis

      8

      GERD Treatment and Management

      8.1

      Lifestyle Modifications

      8.2

      Pharmacological Therapy

      8.3

      Endoscopic and Surgical Therapy

      8.4

      Treatment Guidelines

      8.5

      Treatment Algorithm

      9

      GERD Patient Journey

      10

      Epidemiology and Patient Population

      10.1

      Key Findings

      10.2

      Assumptions and Rationale

      10.3

      Total Diagnosed Prevalent Cases of GERD in the 7MM

      10.4

      The United States

      10.4.1

      Prevalent Cases of GERD in the United States

      10.4.2

      Diagnosed Prevalent Cases of GERD in the United States

      10.4.3

      Gender-specific Cases of GERD in the United States

      10.4.4

      Age-specific Cases of GERD in the United States

      10.4.5

      Type Specific Cases of GERD in the United States

      10.4.6

      Grade-specific Cases of GERD (erosive esophagitis) in the United States

      10.4.7

      Total Treated Cases of GERD in the United States

      10.5

      EU4 and the UK

      10.6

      Japan

      11

      Marketed GERD Therapies

      11.1

      VOQUEZNA (Vonoprazan): Phathom Pharmaceuticals/Takeda

      11.1.1

      Product Description

      11.1.2

      Regulatory Milestones

      11.1.3

      Other Developmental Activities

      11.1.4

      Summary of Pivotal Trials

      11.1.5

      Clinical Developmental Activities

      11.1.5.1

      Clinical Trials Information

      11.1.6

      Safety and Efficacy

      11.1.7

      Analyst Views

      12

      Emerging GERD Therapies

      12.1

      Key Cross Competition

      12.2

      BLI5100 (Tegoprazan): Braintree Laboratories

      12.2.1

      Product Description

      12.2.2

      Other Developmental Activities

      12.2.3

      Clinical Developmental Activities

      12.2.3.1

      Clinical trial information

      12.2.4

      Safety and Efficacy

      12.2.5

      Analyst View

      12.3

      Linaprazan Glurate: Cinclus Pharma

      13

      GERD Market: Seven Major Market Analysis

      13.1

      Key Findings

      13.2

      Key GERD Market Forecast Assumptions

      13.3

      Gastroesophageal Reflux Disease Market Outlook

      13.4

      Conjoint Analysis

      13.5

      Total Market Size of GERD in the 7MM

      13.6

      Market Size of GERD by Therapies in the 7MM

      13.7

      GERD Market Size in the United States

      13.7.1

      Total Market Size of GERD in the United States

      13.7.2

      Market Size of GERD by Therapies in the United States

      13.8

      GERD Market Size in EU4 and the UK

      13.9

      GERD Market Size in Japan

      14

      KOL Views on GERD

      15

      GERD Market SWOT Analysis

      16

      GERD Market Unmet Needs

      17

      Gastroesophageal Reflux Disease Market Access and Reimbursement

      17.1

      The United States

      17.2

      EU4 and the UK

      17.3

      Japan

      17.4

      Reimbursement Scenario in GERD

      18

      Bibliography

      19

      GERD Market Report Methodology

      Related Reports

      Gastroesophageal Reflux Disease Clinical Trial Analysis

      Gastroesophageal Reflux Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GERD companies, including Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, among others.

      Gastroparesis Market

      Gastroparesis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gastroparesis companies, including Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, among others.

      Eosinophilic Esophagitis Market

      Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key eosinophilic esophagitis companies, including Bristol Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Allakos, Pfizer, Revolo Biotherapeutics, EsoCap AG, NexEos Diagnostics, Inc., Celgene, among others.

      Eosinophilic Gastroenteritis Market

      Eosinophilic Gastroenteritis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key eosinophilic gastroenteritis companies including Allakos, AstraZeneca, among others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us

      Shruti Thakur
      [email protected]  
      +14699457679
      www.delveinsight.com 

      Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Pharmaceuticals

      Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.